Ann: Transformative Portfolio Expansion Presentation, page-4

I haven't done much reading on this but if any of you are keen to read more about it and analyse it for us, here are papers that are related to the asset:
- Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 - https://clinicaltrials.gov/ct2/show/NCT02890758?term=david+wald&draw=2&rank=1 - this seems to be the trial theyre referring too. It's combined with ALT803 which is a IL-15 super agonist which enhances NK cell function.
- IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447472/
- An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck - https://pubmed.ncbi.nlm.nih.gov/31338557/
- First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992862/
- Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells https://www.nature.com/articles/s41598-019-51287-6 - this is the nature article that they are referring to in the announcement.

This seems to be a manufacturing platform for NK cells. I haven't read through all of these papers, but they are the ones that I've found so far from a quick search. Will read through it after work.